| 14 | Prediction censored data | TopicSem | ||
| 17 | Combination chemotherapy in advanced gastric cancer | SysBiol |
| 08 | skin classification | xMutant | ||
| 20 | Synthetic Lethality-based Identifcation of Targets for Anticancer Drugs in the Human Signaling Network | |
J.Club |
| 13 | TP53 Paclitaxel SC Network is Prognostic Factor on Urogenital Cancers | SysBiol | ||
| 27 | NGS Sequencing to Detect Genetic Biomarker of Busulfan Induced Hepatotoxicity | TopicSem |
| 12 | NGS biomarker for busulfan ADR | SysBiol | ||
| 12 | NGS biomarker for busulfan ADR | SysBiol | ||
| 19 | Bipartite approach for Metalab DRUG-ADR network | TopicSem |
| 09 | Inference of Digenic Disruption Networks for Synthetic Cytotoxicity | TopicSem |
| 07 | Non-linear model to predict cytotoxic drug response | SysBiol | ||
| 20 | Microarray data analysis of multi-center breast cancer patients with distant metastasis | TopicSem | ||
| 21 | Inference of candidate Synthetic Cytotoxic Drug (Pyrimethamine, Paclitaxel) | xMutant |
| 06 | SDL gene target drugs and drug sensitivity | TopicSem | ||
| 14 | miRNA analysis pipeline and report format | xMutant |
| 12 | Measuring intratumor heterogeneity by network entropy using RNA-seq data | |
J.Club |
| 17 | Classification and segmentation in convolutional neural network | xMutant | ||
| 29 | Synthetic dosage cancer survival analysis: Methylation and Under-expression | TopicSem |
| 01 | GeneScore calculation strategy | xMutant |
| 16 | Synthetic dosage cancer survival gene pairs | TopicSem |
| 15 | Mutual exclusive network and inference target from drug sensitivity | xMutant | ||
| 29 | ENCAPP: elastic-net-based prognosis prediction and biomarker discovery for human cancers | |
J.Club |
| 26 | Synthetic dosage cancer survival | TopicSem | ||
| 9 | WGCNA Network analysis of Microarray data | SysBiol |
| 04 | Pan-cancer Analysis for Disrupted Gene Network via Developmental Origins | TopicSem | ||
| 25 | Microarray analysis (Illumina), research results | SysBiol |
| 19 | Pan-cancer analysis of the extent and consequences of intratumor heterogeneity | |
J.Club | |
| 22 | How to use MuTect, ExomeCNV and EXPANDS. | xMutant | ||
| 23 | intratumor heterogeneity analysis | TopicSem |
| 03 | Overexpression using normal expression in SDL analysis | xMutant | ||
| 23 | Synthetic Cancer Survival by Dosage | TopicSem |
| 07 | Current_progress_of_the_SDL_analysis | TopicSem |
| 21 | Synthetic dosage lethality in LUAD | xMutant |
| 22 | Synthetic Dosage Lethality in Lung Adenocarcinoma | TopicSem |
| 09 | Improved data analysis for the MinION nanopore sequencer | |
J.Club | |
| 18 | RNAseq data Filtering and Normalization and SDL regression analysis | TopicSem |
| 15 | RNAseq Normalization and SDL regression analysis | TopicSem |
| 16 | What is overexpression in Synthetic dosage lethality | TopicSem |
| 26 | SG14 | Seminar |